MTT5
MTT5, a TLR7 agonist, is conjugated to Deruxtecan to create a bifunctional agent for HER2-positive solid tumors. This conjugate combines targeted tumor cell killing with immune system activation via TLR7 stimulation, supporting research in antibody-drug conjugates and immuno-oncology for both in vitro and in vivo studies.
Product Specifications
Field of Research
Immunology & Inflammation
Molecular Formula
C22H27N7O4
Molecular Weight
453.49
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
